Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncologyfocused drug development company, is pleased to announce that it is supporting the University of Sydney on a molecularly-guided phase II clinical study to

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) today announced that Chief Executive Officer and Managing Director, Dr James Garner, has resigned from the company. Dr John Friend, Chief Medical Officer of Kazia, will immediately assume the role of Chief Executive Officer, and will in due course join the Board as Managing Director.

https://www.biorxiv.org/content/10.1101/2023.04.17.537256v1

– Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is pleased to have received notification from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

HC Wainwright & Co. analyst Sean Lee upgrades Kazia Therapeutics (NASDAQ:KZIA) from Neutral to Buy and announces $2 price target.

Gainers AMC Entertainment Hldg Pref Equity Units (NYSE: APE) gained 28.4% to $1.90 in pre-market trading. AMC Entertainment Holdings stated it agreed to settle litigation and move forward with converting its preferred stock into common shares.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is pleased to announce that it has entered into a collaboration with the Australian and New Zealand Children's Haematology / Oncology Group (ANZCHOG) for a phase II clinical study examining paxalisib in children with advanced solid tumours, including brain tumours.

Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.